CapsoVision (NASDAQ:CV) Coverage Initiated by Analysts at Benchmark

Key Points

• CapsoVision has received a "speculative buy" rating from Benchmark analysts, with a target price of $5.00, indicating a potential upside of 25% from its previous close.
• Other brokerages, including Roth Capital, set a price target of $6.00 and rated the stock as a "buy," while Wall Street Zen upgraded it to a "hold" rating.
• As of the report, CapsoVision shares were trading at $4.00, with a twelve-month trading range between $3.49 and $5.72.

Benchmark started coverage on shares of CapsoVision (NASDAQ:CV - Free Report) in a research note published on Monday morning, Marketbeat.com reports. The brokerage issued a speculative buy rating and a $5.00 price objective on the stock.

Several other equities research analysts also recently weighed in on the company. Roth Capital set a $6.00 price target on CapsoVision and gave the stock a "buy" rating in a report on Monday. Wall Street Zen raised shares of CapsoVision to a "hold" rating in a research note on Sunday, July 13th.

CapsoVision Stock Performance

Shares of CapsoVision stock traded down $0.18 during trading hours on Monday, reaching $3.93. The company's stock had a trading volume of 96,821 shares, compared to its average volume of 460,252. CapsoVision has a one year low of $3.49 and a one year high of $5.72.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.